Olga M Fryszman from 11274 Ganesta Rd, San Diego, CA 92126, age 58, Phone: (858)2714397

5-Membered Heterocycle-Based P38 Kinase Inhibitors
view source
US Patent:

7863314, Jan 4, 2011
Filed:

Jun 25, 2004
Appl. No.:

10/877534
Inventors:

Olga M. Fryszman - San Diego CA, US
Hengyuan Lang - San Diego CA, US
Jiong Lan - San Diego CA, US
Edcon Chang - San Diego CA, US
Yunfeng Fang - San Diego CA, US
Assignee:

Novartis AG - Basel
International Classification:

A01N 43/56
C07D 231/00
US Classification:

514407, 5483714
Abstract:

Provided are 5-membered heterocycle-based p38 kinase inhibitors. Further provided are pyrazole and imidazole-based p38 kinase, including p38α and p38β kinase, inhibitors. Pharmaceutical compositions containing the compounds are also provided. Methods of use of the compounds and compositions are also provided, including methods of treatment, prevention, or amelioration of one or more symptoms of p38 kinase mediated diseases and disorders, including, but not limited to, inflammatory diseases and disorders.

5-Membered Heterocycle-Based P38 Kinase Inhibitors
view source
US Patent:

8242117, Aug 14, 2012
Filed:

Nov 19, 2010
Appl. No.:

12/950649
Inventors:

Olga M. Fryszman - San Diego CA, US
Hengyuan Lang - San Diego CA, US
Jiong Lan - Emeryville CA, US
Edcon Chang - San Diego CA, US
Yunfeng Fang - San Diego CA, US
Assignee:

Novartis AG - Basel
International Classification:

A61K 31/5355
A61K 31/415
A61K 31/4164
A61K 31/4245
A61K 31/4439
A61K 31/506
A61K 31/497
A61P 13/00
A61P 9/00
A61P 11/06
A61P 25/28
A61P 31/12
A61P 1/00
US Classification:

5142365, 51425405, 514256, 514341, 514364, 514386, 514407
Abstract:

Provided are 5-membered heterocycle-based p38 kinase inhibitors. Further provided are pyrazole and imidazole-based p38 kinase, including p38α and p38β kinase, inhibitors. Pharmaceutical compositions containing the compounds are also provided. Methods of use of the compounds and compositions are also provided, including methods of treatment, prevention, or amelioration of one or more symptoms of p38 kinase mediated diseases and disorders, including, but not limited to, inflammatory diseases and disorders.

5-Membered Heterocycle-Based P38 Kinase Inhibitors
view source
US Patent:

8410160, Apr 2, 2013
Filed:

Jun 22, 2012
Appl. No.:

13/530919
Inventors:

Olga M. Fryszman - San Diego CA, US
Hengyuan Lang - San Diego CA, US
Jiong Lan - Moraga CA, US
Edcon Chang - San Diego CA, US
Yunfeng Fang - San Diego CA, US
Assignee:

Novartis AG - Basel
International Classification:

A61K 31/415
A61P 13/12
A61P 9/00
A61P 11/00
US Classification:

514407
Abstract:

Provided are 5-membered heterocycle-based p38 kinase inhibitors. Further provided are pyrazole and imidazole-based p38 kinase, including p38α, and p38β kinase, inhibitors. Pharmaceutical compositions containing the compounds are also provided. Methods of use of the compounds and compositions are also provided, including methods of treatment, prevention, or amelioration of one or more symptoms of p38 kinase mediated diseases and disorders, including, but not limited to, inflammatory diseases and disorders.

5-Membered Heterocycle-Based P38 Kinase Inhibitors
view source
US Patent:

8580838, Nov 12, 2013
Filed:

Feb 25, 2013
Appl. No.:

13/775963
Inventors:

- Basel, CH
Olga M. Fryszman - San Diego CA, US
Edcon Chang - San Diego CA, US
Jiong Lan - Morago CA, US
Yunfeng Fang - San Diego CA, US
Assignee:

Novartis AG - Basel
International Classification:

A61K 31/415
A61P 13/12
A61P 9/00
A61P 11/00
US Classification:

514407
Abstract:

Provided are 5-membered heterocycle-based p38 kinase inhibitors. Further provided are pyrazole and imidazole-based p38 kinase, including p38α, and p38β kinase, inhibitors. Pharmaceutical compositions containing the compounds are also provided. Methods of use of the compounds and compositions are also provided, including methods of treatment, prevention, or amelioration of one or more symptoms of p38 kinase mediated diseases and disorders, including, but not limited to, inflammatory diseases and disorders.

.Alpha.-Phosphonosulfinic Squalene Synthetase Inhibitors
view source
US Patent:

54479223, Sep 5, 1995
Filed:

Aug 24, 1994
Appl. No.:

8/295121
Inventors:

R. Michael Lawrence - Yardley PA
Scott A. Biller - Ewing NJ
Olga M. Fryszman - Princeton NJ
Assignee:

Bristol-Myers Squibb Company - Princeton NJ
International Classification:

A61K 3166
C07F 938
C07F 940
US Classification:

514129
Abstract:

alpha. -Phosphonosulfinate compounds are provided which inhibit the enzyme squalene synthetase and thereby inhibit cholesterol biosynthesis. These compounds have the formula ##STR1## wherein R. sup. 2 is OR. sup. 5 or R. sup. 5a ; R. sup. 3 and R. sup. 5 are independently H, alkyl, arylalkyl, aryl or cycloalkyl; R. sup. 5a is alkyl, arylalkyl or aryl; R. sup. 4 is H or pharmaceutically acceptable cation;, Z is H, halogen, lower alkyl or lower alkenyl; and R. sup. 1 is a lipophilic group which contains at least 7 carbons and is alkyl, alkenyl, alkynyl, mixed alkenyl-alkynyl, aryl, arylalkyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, cycloheteroalkyl, cycloheteroalkylalkyl; as further defined above; including pharmaceutically acceptable salts.

Methods Of Preparing .Alpha.-Phosphonosulfinate Squalene Synthetase Inhibitors
view source
US Patent:

55435424, Aug 6, 1996
Filed:

May 22, 1995
Appl. No.:

8/445604
Inventors:

R. Michael Lawrence - Yardley PA
Scott A. Biller - Ewing NJ
Olga M. Fryszman - Princeton NJ
International Classification:

C07F 938
C07F 940
US Classification:

558 87
Abstract:

alpha. -Phosphonosulfinate compounds are provided which inhibit the enzyme squalene synthetase and thereby inhibit cholesterol biosynthesis. These compounds have the formula ##STR1## wherein R. sup. 2 is OR. sup. 5 or R. sup. 5a ; R. sup. 3 and R. sup. 5 are independently H, alkyl, arylalkyl, aryl or cycloalkyl; R. sup. 5a is alkyl, arylalkyl or aryl; R. sup. 4 is H or a pharmaceutically acceptable cation; Z is H, halogen, lower alkyl or lower alkenyl; and R. sup. 1 is a lipophilic group which contains at least 7 carbons and is alkyl, alkenyl, alkynyl, mixed alkenyl-alkynyl, aryl, arylalkyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, cycloheteroalkyl, cycloheteroalkylalkyl; including pharmaceutically acceptable salts.